Marksans Pharma Board of Directors
Get the latest insights into the leadership at Marksans Pharma. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Harshavardhan Panigrahi | Company Secretary & Compliance Officer |
| Mark Saldanha | Chairman & Managing Director |
| Sandra Saldanha | Whole Time Director |
| Varddhman Vikramaditya Jain | Whole Time Director |
| Digant Mahesh Parikh | Non Executive Independent Director |
| Abhinna Sundar Mohanty | Non Executive Independent Director |
| Shailaja Vardhan | Non Executive Independent Director |
| Sunny Sharma | Non Independent & Non Executive Director |
| Srinivas Mishra | Non Executive Independent Director |
Marksans Pharma FAQs
The board at Marksans Pharma consists of experienced professionals, including Harshavardhan Panigrahi, Mark Saldanha, and others, overseeing the company’s strategic and corporate governance.
Directors at Marksans Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Harshavardhan Panigrahi is the current chairman at Marksans Pharma.
Executive directors at Marksans Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Marksans Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Marksans Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
